Literature DB >> 11102935

Unbalanced 4;6 translocation and progressive renal disease.

M E Pierpont1, A S Hentges, L J Gears, B Hirsch, A Sinaiko.   

Abstract

Two sibs are described with an unbalanced 4;6 translocation resulting in partial trisomy 6p and monosomy for distal 4p. Growth retardation, psychomotor retardation, and characteristic facial appearance are present. The facial anomalies include high prominent forehead, blepharoptosis, blepharophimosis, high nasal bridge, bulbous nose, long philtrum, small mouth with thin lips, and low-set ears. Both children have small kidneys and have had proteinuria since early childhood. The older boy developed progressive renal disease including hypertension and renal failure necessitating renal transplantation at age 18 years. Renal biopsy of the younger girl also indicates significant renal involvement. Progressive renal disease is likely an important part of the trisomy 6p phenotype. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2000        PMID: 11102935

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  3 in total

1.  Glo-In-One: holistic glomerular detection, segmentation, and lesion characterization with large-scale web image mining.

Authors:  Tianyuan Yao; Yuzhe Lu; Jun Long; Aadarsh Jha; Zheyu Zhu; Zuhayr Asad; Haichun Yang; Agnes B Fogo; Yuankai Huo
Journal:  J Med Imaging (Bellingham)       Date:  2022-06-20

2.  Subtelomeric FISH analysis in 76 patients with syndromic developmental delay/intellectual disability.

Authors:  Elga F Belligni; Elisa Biamino; Cristina Molinatto; Jole Messa; Mauro Pierluigi; Francesca Faravelli; Orsetta Zuffardi; Giovanni B Ferrero; Margherita Cirillo Silengo
Journal:  Ital J Pediatr       Date:  2009-04-27       Impact factor: 2.638

3.  Glomerulopathy in patients with distal duplication of chromosome 6p.

Authors:  Augustina Jankauskienė; Magdalena Koczkowska; Anna Bjerre; Joanna Bernaciak; Franz Schaefer; Beata S Lipska-Ziętkiewicz
Journal:  BMC Nephrol       Date:  2016-03-21       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.